View of Comparative Cost Efficiency of the Originator Drug of Infliximab and its Biosimilar for the Treatment of Rheumatoid Arthritis in the MENA Region

Return to Article Details Comparative Cost Efficiency of the Originator Drug of Infliximab and its Biosimilar for the Treatment of Rheumatoid Arthritis in the MENA Region Download Download PDF